Ozempic Gastroparesis Settlement: Washington Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

For decades, mass production in the health and science information domain has focused on broad public education, emphasizing general wellness, disease prevention, and the safe use of medications. This legacy established a foundation of trust, where consumers learned to navigate complex medical landscapes through accessible, authoritative guidance. As the pharmaceutical industry expanded, so did the need to address specific adverse outcomes linked to widely prescribed treatments. The transition from general health literacy to targeted risk awareness is a natural evolution, particularly when a medication’s widespread use reveals previously underrecognized complications. In this context, the emergence of concerns surrounding glucagon-like peptide-1 receptor agonists, such as Ozempic, marks a pivotal shift. While these therapies were initially celebrated for their efficacy in managing chronic conditions, post-market surveillance has highlighted potential gastrointestinal adverse events, including gastroparesis. This condition, characterized by delayed gastric emptying, can lead to significant morbidity and has prompted legal scrutiny. The focus now narrows from population-level health education to individual exposure and liability, especially for those who developed severe complications after prolonged use. For individuals in Washington who have experienced such outcomes, the question of accountability becomes paramount. This transition underscores the need for specialized legal guidance to navigate the intersection of pharmaceutical mass production, patient safety, and personal injury claims.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes. However, its use has been associated with a range of gastrointestinal adverse reactions, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacological mechanisms linking Ozempic to this condition, and the risk and settlement considerations for affected patients. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and poor glycemic control, complicating diabetes management. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Pharmacological Mechanism and Clinical Evidence

The pharmacological mechanism by which Ozempic may contribute to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 slows gastric emptying, which is part of its therapeutic effect on postprandial glucose. However, excessive or prolonged slowing can lead to gastroparesis. The drug's labeling notes gastrointestinal adverse reactions with a frequency of <5%, including dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, suggesting a mechanistic link through delayed gastric emptying. Risk considerations center on the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific adverse event. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not provide a dedicated warning for gastroparesis, which may affect patients' ability to recognize and report symptoms early.

Settlement Considerations for Washington Residents

For affected patients, settlement-related considerations include documenting the timeline between Ozempic exposure and the onset of gastroparesis symptoms. Clinical trials show that gastrointestinal adverse reactions often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting a temporal relationship. Patients who develop gastroparesis after starting Ozempic may need to establish causality through medical records, including gastric emptying studies and documentation of symptom onset relative to drug initiation. Settlement considerations for Washington residents involve legal factors such as the statute of limitations for product liability claims, which typically runs from the date of injury or discovery. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their case. Evidence of harm may include medical records showing gastroparesis diagnosis, Ozempic prescription history, and any discontinuation of the drug due to adverse effects. The discontinuation rates in clinical trials—3.1% for 0.5 mg and 3.8% for 1 mg—highlight that gastrointestinal issues are a common reason for stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In summary, Ozempic is associated with gastrointestinal adverse reactions that can include gastroparesis, supported by clinical trial data showing increased rates of nausea, vomiting, and related symptoms. The drug's mechanism of slowing gastric emptying provides a plausible pathway. However, the labeling does not specifically warn about gastroparesis, which may impact risk awareness. Patients in Washington who have developed gastroparesis after using Ozempic should seek legal advice to explore settlement options, ensuring they document the exposure timeline and medical evidence of harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its therapeutic effect, but excessive slowing can cause gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What evidence do I need for an Ozempic gastroparesis settlement in Washington?

You need to document the timeline between Ozempic exposure and gastroparesis onset, including medical records such as gastric emptying studies, prescription history, and any discontinuation due to adverse effects. Clinical trial data shows gastrointestinal issues often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Consult a pharmaceutical litigation attorney to evaluate your case and ensure compliance with Washington's statute of limitations.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.